DelveInsight’s, “Cholangiocarcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including Cholangiocarcinoma clinical trials and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Cholangiocarcinoma Emerging drugs, the Cholangiocarcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Cholangiocarcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Cholangiocarcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Cholangiocarcinoma clinical trials studies, Cholangiocarcinoma NDA approvals (if any), and product development activities comprising the technology, Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Cholangiocarcinoma Pipeline Report

 

• Over 70+ Cholangiocarcinoma companies are evaluating 70+ Cholangiocarcinoma pipeline therapies in various stages of development, and their anticipated acceptance in the Cholangiocarcinoma market would significantly increase market revenue.

 

• The leading Cholangiocarcinoma Companies include QED Therapeutics, Taiho Oncology, Merck Sharp & Dohme Corp, EMD Serono/Merck, Eisai Inc., 3D Medicines, PCI Biotech AS, Basilea Pharmaceutical, Newish Technology (Beijing) Co., Ltd., Bristol-Myers Squibb, Hutchison Medipharma Limited, Jiangsu HengRui Medicine, TransThera Sciences, RedHill Biopharma, AstraZeneca, Janssen Pharmaceuticals, and others.

 

• Promising Cholangiocarcinoma Pipeline Therapies includes Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib,  XmAb®22841, STP705,  Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009, and others.

 

• The Cholangiocarcinoma companies and academics are working to assess challenges and seek opportunities that could influence Cholangiocarcinoma R&D. The Cholangiocarcinoma pipeline therapies under development are focused on novel approaches to treat/improve Cholangiocarcinoma.

 

Request a sample and discover the recent breakthroughs happening in the Cholangiocarcinoma Pipeline landscape @ Cholangiocarcinoma Pipeline Outlook Report

 

Cholangiocarcinoma Overview

Cholangiocarcinoma is an epithelial cell malignancy arising from varying locations within the biliary tree showing markers of cholangiocyte differentiation. The most contemporary classification based on anatomical location includes intrahepatic, perihilar, and distal cholangiocarcinoma.  Many cases of cholangiocarcinoma arise de novo and do not have a specific risk factor, but there are a number of risk factors that have been identified, including primary hepatobiliary disease, genetic disorders, toxic exposures, and infections. Similar to many malignancies, cholangiocarcinoma arises from precursor lesions such as the more common biliary intraepithelial neoplasia and the less common intraductal papillary mucinous neoplasm.

 

Recent Developmental Activities in the Cholangiocarcinoma Treatment Landscape

 

• In February 2022, HUTCHMED initiated a Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors, including intrahepatic cholangiocarcinoma in China. HMPL-453 is also being evaluated as monotherapy in Phase II clinical trials in China.

 

• In 2022, Basilea will continue its oncology activities to ensure project continuity and progression. For derazantinib, the company will continue the FIDES-01 study in intrahepatic cholangiocarcinoma (iCCA).

 

• In January 2022, US FDA cleared the Investigational New Drug (IND) application for KIN-3248 being developed by Kinnate Biopharma. KIN-3248 is a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinoma.

 

For further information, refer to the detailed Cholangiocarcinoma Drugs Launch, Cholangiocarcinoma Developmental Activities, and Cholangiocarcinoma News, click here for Cholangiocarcinoma Ongoing Clinical Trial Analysis

 

Cholangiocarcinoma Emerging Drugs Profile

 

• TAS-120: Taiho Oncology

Futibatinib (TAS-120) is an investigational, oral, potent, selective, and irreversible small-molecule inhibitor of FGFR1, 2, 3 and 4 being studied as a potential treatment for patients with advanced solid tumors with FGFR1-4 genetic aberrations, including cholangiocarcinoma, who were previously treated with chemotherapy or other therapies. Futibatinib selectively and irreversibly binds to the ATP binding pocket of FGFR1-4 resulting in the inhibition of FGFR-mediated signal transduction pathways, reduced tumor cell proliferation and increased tumor cell death in tumors with FGFR1-4 genetic aberrations. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for futibatinib for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements, including gene fusions in February 2021 based on efficacy and safety results from the FOENIX-CCA2 study. The FDA Office of Orphan Drug Development granted futibatinib orphan drug status for the treatment of cholangiocarcinoma in May 2018.

 

• Pembrolizumab: Merck Sharp & dohme

Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. It is currently being evaluated in Phase III stage of development to treat biliary tract cancer.

 

• E7090: Eisai

Discovered in-house by Eisai’s Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3. Distinct from prior known FGFR inhibitors, E7090 has a basic structure which lacks the dimethoxyphenyl moiety, and in a kinetic interaction analysis study, it was observed that E7090 demonstrates antitumor effects due to inhibition of kinase activity with a binding mode (Type V) that exhibits rapid and potent binding as well as high selectivity to FGFR.1 A Phase II clinical trial (Study 201) of E7090 is underway in Japan and China to evaluate efficacy and safety in patients with cholangiocarcinoma with FGFR2 gene fusion. E7090 received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan.

 

Cholangiocarcinoma Pipeline Segmentation

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

 

Product Type

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Cholangiocarcinoma Pipeline Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Cholangiocarcinoma. The companies which have their Cholangiocarcinoma drug candidates in the most advanced stage, i.e. Phase III include, ImmunoGen.

 

Find out more about the Cholangiocarcinoma Pipeline Segmentation, Therapeutics Assessment, Cholangiocarcinoma Emerging Drugs @ Cholangiocarcinoma Treatment Landscape

 

Scope of the Cholangiocarcinoma Pipeline Report

 

• Coverage- Global

 

• Cholangiocarcinoma Companies- QED Therapeutics, Taiho Oncology, Merck Sharp & Dohme Corp, EMD Serono/Merck, Eisai Inc., 3D Medicines, PCI Biotech AS, Basilea Pharmaceutical, Newish Technology (Beijing) Co., Ltd., Bristol-Myers Squibb, Hutchison Medipharma Limited, Jiangsu HengRui Medicine, TransThera Sciences, RedHill Biopharma, AstraZeneca, Janssen Pharmaceuticals, and others.

 

• Cholangiocarcinoma Pipeline Therapies– Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib,  XmAb®22841, STP705,  Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009,and others.

 

• Cholangiocarcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Cholangiocarcinoma Pipeline Companies and Therapies, click here @ Cholangiocarcinoma Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Cholangiocarcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Mirvetuximab Soravtansine: ImmunoGen
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Gimatecan: Lee’s Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I/II)
13. TX200-TR101: Sangamo therapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Cholangiocarcinoma Key Companies
17. Cholangiocarcinoma Key Products
18. Cholangiocarcinoma- Unmet Needs
19. Cholangiocarcinoma- Market Drivers and Barriers
20. Cholangiocarcinoma- Future Perspectives and Conclusion
21. Cholangiocarcinoma Analyst Views
22. Cholangiocarcinoma Key Companies
23. 23.   Appendix

 

Got Queries? Find out the related information on Cholangiocarcinoma Mergers and acquisitions, Cholangiocarcinoma Licensing Activities @ Cholangiocarcinoma Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services